Target intelligence / Profile preview

Hemoglobin subunit gamma-2 (HBG2)

Target
HBG2
Molecular classification
Globin protein, Hemoglobin subunit, Oxygen transporter, Other (due to its regulatory role in development)
01

Overview

Hemoglobin subunit gamma-2 is a globin protein encoded by the HBG2 gene and forms part of fetal hemoglobin (HbF), comprising two alpha and two gamma chains. This subunit predominates at birth and is essential for oxygen transport in fetal development, with expression normally silenced postnatally. Persistent or reactivated HBG2 expression can ameliorate clinical severity in hemoglobinopathies such as sickle cell disease and beta-thalassemia. Genetic variations in the HBG2 promoter and regulatory pathways control its expression, making HBG2 a major therapeutic target for pharmacologic and gene editing strategies seeking to increase HbF in affected patients

Other names
HBG2HBG-T1Gamma-2-globinHemoglobin gamma-2 chainHemoglobin gamma-G chainfetal hemoglobin F subunit gamma 2TNCYG-gamma globin
02

Mechanism of action

Activation of HBG2 promoter to induce HbF synthesis (by hydroxyurea, decitabine, butyrate derivatives) Epigenetic modulation of transcriptional regulators/repressor complexes (e.g., BCL11A, NuRD)

03

Biological functions

Oxygen transportFormation of fetal hemoglobin (HbF, major oxygen carrier in fetus)Developmental regulation of hemoglobin synthesisModifier of hemoglobinopathy phenotypes
04

Disease associations

Beta-thalassemiaSickle cell diseaseHereditary persistence of fetal hemoglobin (HPFH)Cyanosis (transient neonatal)Other hemoglobinopathies
05

Safety considerations

Overexpression could theoretically result in altered oxygen affinity and tissue hypoxiaRisk of drug toxicity (hydroxyurea-related cytopenias, long-term effects)Unintended genetic disruption in gene editing approachesPotential for autoimmune or inflammatory responses with novel therapies
06

Interacting drugs

Hydroxyurea (induces HbF expression via regulatory effect on HBG2)

3 more in the full profile.

07

Biomarkers

HbF levels (percentage of fetal hemoglobin in blood; reflects HBG2 activity)XmnI polymorphism (–158 C>T upstream of HBG2 promoter correlating with higher HbF)Specific HBG2 promoter mutations

Beyond the preview

Go deeper on Hemoglobin subunit gamma-2 (HBG2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hemoglobin subunit gamma-2 (HBG2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call